RxDoctor Payments DataLook up a doctor →

Vijay Mehta, MD

Cardiovascular Disease · Elkhart, INNPI 1801921325

Payments from drug & device makers

$924,593in general payments, 2019–2025

Across 883 payments — averaging $1047.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$277K
  • Boehringer Ingelheim International GmbH$199K
  • Novartis$183K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$95K
  • Bayer$65K
  • AstraZeneca$60K
  • plus $46K from 38 others

What the payments were for

  • Travel & lodging$70314%
  • Food & beverage$4,39886%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$924,593 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$181,789
Medicare patients
1,233
Services billed
3,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban423$499,138
EntrestoSacubitril/Valsartan335$377,035
XareltoRivaroxaban221$234,833
JardianceEmpagliflozin69$73,504
FarxigaDapagliflozin Propanediol36$38,809
Repatha SureclickEvolocumab19$30,287
MultaqDronedarone Hcl19$28,546
VerquvoVericiguat17$14,131
BrilintaTicagrelor17$13,850
Repatha SyringeEvolocumab17$13,715
Breo ElliptaFluticasone/Vilanterol17$11,041
NexlizetBempedoic Acid/Ezetimibe12$9,520
Spiriva RespimatTiotropium Bromide11$5,862
Metoprolol Succinate562$5,818
Ranolazine ErRanolazine80$4,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$248$499,138423 claims
NovartisEntresto$183,102$377,035335 claims
Johnson & JohnsonXarelto$474$234,833221 claims
Boehringer IngelheimJardiance, Spiriva Respimat$54$79,36680 claims
AstraZenecaFarxiga, Brilinta$60,055$52,65953 claims
Sanofi-aventis U.S. LLCMultaq$88$28,54619 claims
MerckVerquvo$266$14,13117 claims
Esperion Therapeutics, Inc.Nexlizet$52$9,52012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →